About Synaptotagmin-17
Synaptotagmin-17 (SYT17) is a protein
from Homo sapiens identified by UniProt accession
Q9BSW7, 474 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | Synaptotagmin-17 |
|---|
| UniProt accession | Q9BSW7 |
|---|
| Gene | SYT17 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 474 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (53)
Diseases linked to this target (Open Targets).
- gut microbiome measurement · score 0.32
- Parkinson disease · score 0.30
- body height · score 0.27
- self reported educational attainment · score 0.27
- eosinophil count · score 0.23
- appendicular lean mass · score 0.22
- eosinophil percentage of leukocytes · score 0.21
- diet measurement · score 0.21
- vital capacity · score 0.19
- diastolic blood pressure · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BSW7-F1 | alphafold | PREDICTED | 70.69 | — |
Amino-acid sequence (474 residues)
MAYIQLEPLN EGFLSRISGL LLCRWTCRHC CQKCYESSCC QSSEDEVEIL GPFPAQTPPW LMASRSSDKD GDSVHTASEV PLTPRTNSPD GRRSSSDTSK STYSLTRRIS SLESRRPSSP LIDIKPIEFG VLSAKKEPIQ PSVLRRTYNP DDYFRKFEPH LYSLDSNSDD VDSLTDEEIL SKYQLGMLHF STQYDLLHNH LTVRVIEARD LPPPISHDGS RQDMAHSNPY VKICLLPDQK NSKQTGVKRK TQKPVFEERY TFEIPFLEAQ RRTLLLTVVD FDKFSRHCVI GKVSVPLCEV DLVKGGHWWK ALIPSSQNEV ELGELLLSLN YLPSAGRLNV DVIRAKQLLQ TDVSQGSDPF VKIQLVHGLK LVKTKKTSFL RGTIDPFYNE SFSFKVPQEE LENASLVFTV FGHNMKSSND FIGRIVIGQY SSGPSETNHW RRMLNTHRTA VEQWHSLRSR AECDRVSPAS LEVT
Explore Synaptotagmin-17 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets